Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group.

N Engl J Med. 2006 Aug 17;355(7):653-65.

2.

Daptomycin: a novel agent for Gram-positive infections.

Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, Oleson FB Jr.

Expert Opin Investig Drugs. 1999 Aug;8(8):1223-38.

PMID:
15992147
3.

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Steenbergen JN, Alder J, Thorne GM, Tally FP.

J Antimicrob Chemother. 2005 Mar;55(3):283-8. Epub 2005 Feb 10. Review.

PMID:
15705644
4.

The importance of bactericidal drugs: future directions in infectious disease.

Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ.

Clin Infect Dis. 2004 Nov 1;39(9):1314-20. Epub 2004 Oct 7. Review.

PMID:
15494908
5.

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators.

Clin Infect Dis. 2004 Jun 15;38(12):1673-81. Epub 2004 May 20.

PMID:
15227611
6.

Once-daily dosing in dogs optimizes daptomycin safety.

Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP.

Antimicrob Agents Chemother. 2000 Nov;44(11):2948-53.

7.

Development of daptomycin for gram-positive infections.

Tally FP, DeBruin MF.

J Antimicrob Chemother. 2000 Oct;46(4):523-6. Review. No abstract available.

PMID:
11020247
8.

Drug target validation: lethal infection blocked by inducible peptide.

Tao J, Wendler P, Connelly G, Lim A, Zhang J, King M, Li T, Silverman JA, Schimmel PR, Tally FP.

Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):783-6.

9.

Researchers reveal ways to defeat 'superbugs'

Tally FP.

Drug Discov Today. 1999 Sep;4(9):395-398. No abstract available.

PMID:
10461147
10.

Antimicrobial resistance in anaerobes.

Rasmussen BA, Bush K, Tally FP.

Clin Infect Dis. 1997 Jan;24 Suppl 1:S110-20. Review.

PMID:
8994790
11.
12.

Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.

Sum PE, Lee VJ, Testa RT, Hlavka JJ, Ellestad GA, Bloom JD, Gluzman Y, Tally FP.

J Med Chem. 1994 Jan 7;37(1):184-8.

PMID:
8289194
13.

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.

Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP.

Antimicrob Agents Chemother. 1993 Nov;37(11):2270-7.

14.

Antimicrobial resistance in Bacteroides.

Rasmussen BA, Bush K, Tally FP.

Clin Infect Dis. 1993 Jun;16 Suppl 4:S390-400. Review.

PMID:
8324154
15.

Safety profile of piperacillin/tazobactam in phase I and III clinical studies.

Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP.

J Antimicrob Chemother. 1993 Jan;31 Suppl A:113-24.

PMID:
8383652
16.

Antibiotic resistance. Epidemiology and therapeutics.

Neu HC, Duma RJ, Jones RN, McGowan JE Jr, O'Brien TF, Sabath LD, Sanders CC, Schaffner W, Tally FP, Tenover FC, et al.

Diagn Microbiol Infect Dis. 1992 Feb;15(2 Suppl):53S-60S. No abstract available.

PMID:
1737445
17.

Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome.

Rasmussen B, Noller HF, Daubresse G, Oliva B, Misulovin Z, Rothstein DM, Ellestad GA, Gluzman Y, Tally FP, Chopra I.

Antimicrob Agents Chemother. 1991 Nov;35(11):2306-11.

18.

Microbiology and antibiotic resistance in odontogenic infections.

Gorbach SL, Gilmore WC, Jacobus NV, Doku HC, Tally FP.

Ann Otol Rhinol Laryngol Suppl. 1991 Sep;154:40-2. No abstract available.

PMID:
1952683
19.
20.

R-plasmid mediated transfer of beta-lactam resistance in Bacteroides fragilis.

Yamaoka K, Watanabe K, Muto Y, Katoh N, Ueno K, Tally FP.

J Antibiot (Tokyo). 1990 Oct;43(10):1302-6.

21.

Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636.

Rasmussen BA, Gluzman Y, Tally FP.

Antimicrob Agents Chemother. 1990 Aug;34(8):1590-2.

22.

Candidal meningitis following bacterial meningitis.

Gelfand MS, McGee ZA, Kaiser AB, Tally FP, Moses J.

South Med J. 1990 May;83(5):567-70.

PMID:
2188372
23.

Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.

Cuchural GJ Jr, Tally FP, Jacobus NV, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C.

Antimicrob Agents Chemother. 1990 Mar;34(3):479-80.

24.

Imipenem resistance in Bacteroides distasonis mediated by a novel beta-lactamase.

Hurlbut S, Cuchural GJ, Tally FP.

Antimicrob Agents Chemother. 1990 Jan;34(1):117-20.

25.
26.

Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.

Kuck NA, Petersen PJ, Weiss WJ, Jacobus NV, Testa RT, Tally FP.

J Chemother. 1989 Jul;1(4 Suppl):105-6. No abstract available.

PMID:
16312325
27.

Recurrent tonsillitis: histologic and bacteriologic evaluation.

Bieluch VM, Martin ET, Chasin WD, Tally FP.

Ann Otol Rhinol Laryngol. 1989 May;98(5 Pt 1):332-5.

PMID:
2719449
28.

Permeability to beta-lactams in Bacteroides fragilis.

Cuchural GJ, Hurlbut S, Malamy MH, Tally FP.

J Antimicrob Chemother. 1988 Dec;22(6):785-90.

PMID:
3266619
29.

A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections.

Gilmore WC, Jacobus NV, Gorbach SL, Doku HC, Tally FP.

J Oral Maxillofac Surg. 1988 Dec;46(12):1065-70.

PMID:
3142979
30.

Antibiotic resistance in anaerobic bacteria.

Tally FP, Cuchural GJ Jr.

J Antimicrob Chemother. 1988 Jul;22 Suppl A:63-71.

PMID:
3264832
31.

Factors affecting the choice of antibiotics in mixed infections.

Tally FP.

J Antimicrob Chemother. 1988 Jul;22 Suppl A:87-100.

PMID:
3209540
32.

Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.

Cuchural GJ Jr, Tally FP, Jacobus NV, Aldridge K, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C, et al.

Antimicrob Agents Chemother. 1988 May;32(5):717-22.

33.

Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species.

Jacobus NV, Tally FP.

Antimicrob Agents Chemother. 1988 Apr;32(4):584-6.

34.

Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections.

Hackford AW, Tally FP, Reinhold RB, Barza M, Gorbach SL.

Arch Surg. 1988 Mar;123(3):322-6.

PMID:
3277587
35.

Antimicrobial resistance in oral and colonic bacteroides.

Crook DW, Cuchural GJ Jr, Jacobus NV, Tally FP.

Scand J Infect Dis Suppl. 1988;57:55-64. Review.

PMID:
3074473
36.
37.
38.

Safety profile of cefixime.

Tally FP, Desjardins RE, McCarthy EF, Cartwright K.

Pediatr Infect Dis J. 1987 Oct;6(10):976-80.

PMID:
3320926
39.

Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.

Bieluch VM, Cuchural GJ, Snydman DR, Gorbach SL, Tally FP.

Diagn Microbiol Infect Dis. 1987 Jun;7(2):119-26.

PMID:
3652652
40.

Management of patients with intraabdominal infection due to colonic perforation.

Tally FP, Ho JL.

Curr Clin Top Infect Dis. 1987;8:266-95. Review. No abstract available.

PMID:
3077280
41.

Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis.

Cuchural GJ Jr, Malamy MH, Tally FP.

Antimicrob Agents Chemother. 1986 Nov;30(5):645-8.

42.

In-vitro activity of cefoperazone-sulbactam against Bacteroides species.

Souza Dias MB, Jacobus NV, Tally FP.

J Antimicrob Chemother. 1986 Oct;18(4):467-71.

PMID:
3021709
43.

Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy.

Cuchural GJ Jr, Tally FP.

Drug Intell Clin Pharm. 1986 Jul-Aug;20(7-8):567-73.

PMID:
3488895
44.

Bacteriology of hospital-acquired pneumonia.

Bartlett JG, O'Keefe P, Tally FP, Louie TJ, Gorbach SL.

Arch Intern Med. 1986 May;146(5):868-71.

PMID:
3516102
45.

Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis.

Cuchural GJ Jr, Tally FP, Storey JR, Malamy MH.

Antimicrob Agents Chemother. 1986 May;29(5):918-20.

46.

Activity of cefotetan against anaerobic bacteria.

Dias MB, Jacobus NV, Tally FP, Gorbach SL.

Diagn Microbiol Infect Dis. 1986 Apr;4(4):359-63.

PMID:
3457672
47.

Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections.

Tally FP, Kellum JM, Ho JL, O'Donnell TF, Barza M, Gorbach SL.

Antimicrob Agents Chemother. 1986 Feb;29(2):244-9.

48.

Resistance factors in anaerobic bacteria.

Tally FP, Malamy MH.

Scand J Infect Dis Suppl. 1986;49:56-63. Review.

PMID:
3029859
49.

Tn4400, a compound transposon isolated from Bacteroides fragilis, functions in Escherichia coli.

Robillard NJ, Tally FP, Malamy MH.

J Bacteriol. 1985 Dec;164(3):1248-55.

50.

Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.

Tally FP, Cuchural GJ Jr, Jacobus NV, Gorbach SL, Aldridge K, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, et al.

Antimicrob Agents Chemother. 1985 Nov;28(5):675-7.

Supplemental Content

Loading ...
Support Center